SCHEMBL2886267

SCHEMBL2886267

O=C(Oc1cccc(F)c1OC(=O)c1ccccc1)c1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.72
SLC2A4 P14672 1/20 0.72
KMT2A Q03164 6/20 0.56
MAPT P10636 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
HSD17B10 Q99714 2/20 0.53
ESR1 P03372 2/20 0.53
ESR2 Q92731 2/20 0.53
MEN1 O00255 1/20 0.53
JAK2 O60674 1/20 0.53
USP2 O75604 1/20 0.53
GAA P10253 1/20 0.53
ALOX15 P16050 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
SLC6A3 Q01959 1/20 0.50
LMNA P02545 2/20 0.49
METAP2 P50579 1/20 0.49
METAP1 P53582 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
TOP1 P11387 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10180647 0.89 SLC2A1 (0.57) SLC2A1SLC2A4KMT2AMAPTSMN1; SMN2
SCHEMBL3826754 0.87 KMT2A (0.66) SLC2A1SLC2A4KMT2AMAPTSMN1; SMN2
SCHEMBL1323923 0.85 KMT2A (0.63) SLC2A1SLC2A4KMT2AMAPTSMN1; SMN2
SCHEMBL2882328 0.85 SLC2A1 (0.62) SLC2A1SLC2A4KMT2AMAPTSMN1; SMN2
SCHEMBL10180669 0.84 KMT2A (0.58) SLC2A1SLC2A4KMT2AMAPTSMN1; SMN2
SCHEMBL19183300 0.84 SLC2A1 (1.00) SLC2A1SLC2A4KMT2AMAPTSMN1; SMN2
SCHEMBL30465014 0.84 SLC2A1 (1.00) SLC2A1SLC2A4KMT2AMAPTSMN1; SMN2
SCHEMBL6358969 0.82 SLC2A1 (0.81) SLC2A1SLC2A4KMT2AMAPTSMN1; SMN2
SCHEMBL15283463 0.79 KMT2A (0.56) SLC2A1SLC2A4KMT2AMAPTSMN1; SMN2
SCHEMBL6939316 0.79 KMT2A (0.56) SLC2A1SLC2A4KMT2AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9464144-B2 Enhanced procatalyst composition and process W. R. Grace & Co.—Conn. (US) 2016-10-11 US disclosed
US-9464144-B2 Enhanced procatalyst composition and process W. R. Grace & Co.—Conn. (US) 2016-10-11 US disclosed
EP-2373701-B1 ENHANCED PROCATALYST COMPOSITION AND PROCESS GRACE W R & CO (US) 2016-03-09 EP disclosed
US-20140274668-A1 ENHANCED PROCATALYST COMPOSITION AND PROCESS W. R. GRACE & CO.-CONN. (US) 2014-09-18 US disclosed
US-20140274668-A1 ENHANCED PROCATALYST COMPOSITION AND PROCESS W. R. GRACE & CO.-CONN. (US) 2014-09-18 US disclosed
US-8778826-B2 Enhanced procatalyst composition and process W. R. GRACE & CO.-CONN. (US) 2014-07-15 US disclosed
US-8778826-B2 Enhanced procatalyst composition and process W. R. GRACE & CO.-CONN. (US) 2014-07-15 US disclosed
US-8604235-B2 Production of substituted phenylene aromatic diesters and compositions DOW GLOBAL TECHNOLOGIES LLC (US) 2013-12-10 US disclosed
US-20100204506-A1 Production of Substituted Phenylene Aromatic Diesters and Compositions W. R. GRACE & CO.-CONN. 2010-08-12 US disclosed
US-20100204506-A1 Production of Substituted Phenylene Aromatic Diesters and Compositions W. R. GRACE & CO.-CONN. 2010-08-12 US disclosed
US-20100204506-A1 Production of Substituted Phenylene Aromatic Diesters and Compositions W. R. GRACE & CO.-CONN. 2010-08-12 US disclosed
US-20100173769-A1 Enhanced Procatalyst Composition and Process W. R. GRACE & CO.-CONN. 2010-07-08 US disclosed
US-20100173769-A1 Enhanced Procatalyst Composition and Process W. R. GRACE & CO.-CONN. 2010-07-08 US disclosed
WO-2010078503-A1 ENHANCED PROCATALYST COMPOSITION AND PROCESS DOW GLOBAL TECHNOLOGIES INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204506-A1 Production of Substituted Phenylene Aromatic Diesters and Compositions PAH, DDC, DDT SLC2A1 4553/4885SLC2A4 2908/4885KMT2A 1611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.